MedTrace Logo

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

NCT01398085 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 504

Last updated 2026-05-07

No results posted yet for this study

Summary

IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.

Conditions

Interventions

RADIATION

I131 1.1 GBq

Radio-iodine

OTHER

No Radioactive iodine (No-RAI) ablation

No Radioactive iodine (No-RAI) ablation

Sponsors & Collaborators

Principal Investigators

  • Ujjal Mallick, MBBS MS FRCR · Newcastle-upon-Tyne Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-26
Primary Completion
2031-03-31
Completion
2031-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01398085 on ClinicalTrials.gov